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Severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), the causative agent of 
coronavirus disease 2019 (COVID-19), was 
first detected in Wuhan, China and has since 
spread across continents. Although the globe 
grapples with the COVID-19 pandemic, 
neither a vaccine nor a drug has been proven 
to be effective for prevention and treatment of 
the disease. With millions of individuals are at 
high risk of contracting the disease, there is 
undoubtedly a need for finding a solution to 
control the spread of SARS-CoV-2 (1). 
Probiotics are living microorganisms, which 
exert health-beneficial attributes when 
consumed in sufficient amounts (2). Based on 
mechanism of immune regulation, probiotics 
can be categorized into two distinct groups, 
namely immunostimulatory and 
immunoregulatory probiotics. The former 
induces production of Interleukin-12 (IL-12), 
which stimulates interferon gamma (IFN-γ) in 
natural killer cells and promotes the 
development of T helper 1 (Th1) responses, 
whereas the latter is able to suppress pro-
inflammatory responses through induction of 
IL-10 production and activation of regulatory 
T cells (Tregs) (3). Some probiotics can also 
enhance production of secretory 
Immunoglobulin A (sIgA) in lung tissues (4). 
Furthermore, probiotics are capable of 
interacting with intruding pathogens in several 
ways. For instance, they can bind to viral 
particles or saturate their host receptors, 
resulting in blockade of viral attachment (4). 
The genera Lactobacillus and Bifidobacterium 
are among the most frequently used probiotics 
in the management of various gastrointestinal 
disorders. For example, supernatants of 
Lactobacillus plantarum Probio-38 and 
Lactobacillus salivarius Probio-37 have been 
observed to impede in vitro infectivity of 
transmissible gastroenteritis virus (5), a 
coronavirus infecting enteric and respiratory 
tissues of newborn piglets with a mortality rate 
of almost 100%. This finding suggests that 
probiotics can ameliorate the severity of 
gastrointestinal symptoms caused by 
coronaviruses.  
Accumulating evidence also abounds on the 
prophylaxis and therapeutic effects of 
probiotics against respiratory tract viral 
infections (RTVIs). In this respect, pre-
treatment of human laryngeal epithelial cell 
line HEp-2 and mouse lung epithelial cell line 
MLE12 with Lactobacillus gasseri SBT2055 
(LG2055) suspension significantly protected 
the cells from respiratory syncytial virus 
(RSV) infection (6). In BALB/cCrSlc mice, 
daily oral administration of LG2055 for 21 
days resulted in a perceptible decrement of 
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production as well as up-regulating gene 
expression of type I and type II interferon in 
lung tissues (6). 
 
Figure 1: Possible anti-viral properties of 
probiotics against SARS-CoV-2 infection 
 
In a randomized, double-blind, placebo-
controlled trial, preterm infants receiving oral 
probiotics (Lactobacillus rhamnosus GG, 
ATCC 53103) exhibited a substantially lower 
incidence of RTVIs compared to those 
receiving placebo (7). One study showed that 
oral administration of L. rhamnosus GG is 
useful for achieving a reduction of antibiotics 
prescribed for hospitalized patients with 
ventilator-associated pneumonia (VAP) (2). In 
consistent with these findings, another 
randomized controlled multicenter trial 
demonstrated that consumption of Bacillus 
subtilis and Enterococcus faecalis prevents 
VAP as well as gastric colonization of 
potentially pathogenic microorganisms in 
critically ill patients (8). 
A pilot study demonstrated that nasal spray 
administration of Streptococcus salivarius 
24SMBc for 3 days was well tolerated by all 
20 healthy adult volunteers, of whom 95% 
were colonized by the probiotic in 
rhinopharynx tissues at least in the first 4 h 
after administration (9). According to these 
results, colonization of upper respiratory tract 
with probiotics may confer protection from 
viruses causing pulmonary infections, in 
particular rhinovirus, coronavirus, influenza 
virus, and RSV. 
Based on above-mentioned studies, we 
hypothesize that oral administration or even 
inhalation of aerosolized probiotics employing 
various formulations (in the form of live or 
heat-inactivated microorganisms) not only acts 
as prophylaxis, but also has the potential for 
adjunct therapy against SARS-CoV-2 
infection. Possible beneficial roles of 
probiotics in COVID-19 therapy are depicted 
in Fig. 1. Nevertheless, clinical trials are 
needed to evaluate anti-viral effects of specific 
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